[go: up one dir, main page]

HK1001495A1 - Obesity (ob) peptides capable of modulating body weight of animals, allelic variants, analogs and fragments thereof, derivatives, nucleic acid sequences, vectors, hosts and the like related thereto, and pharmaceutical compositions and related uses - Google Patents

Obesity (ob) peptides capable of modulating body weight of animals, allelic variants, analogs and fragments thereof, derivatives, nucleic acid sequences, vectors, hosts and the like related thereto, and pharmaceutical compositions and related uses Download PDF

Info

Publication number
HK1001495A1
HK1001495A1 HK98100386A HK98100386A HK1001495A1 HK 1001495 A1 HK1001495 A1 HK 1001495A1 HK 98100386 A HK98100386 A HK 98100386A HK 98100386 A HK98100386 A HK 98100386A HK 1001495 A1 HK1001495 A1 HK 1001495A1
Authority
HK
Hong Kong
Prior art keywords
body weight
nucleic acid
present
vectors
modulators
Prior art date
Application number
HK98100386A
Other languages
English (en)
Chinese (zh)
Other versions
HK1001495B (en
Inventor
M Friedman Jeffery
Zhang Yiying
Proenca Ricardo
Maffei Margherita
L Halaas Jeffrey
Gajiwala Ketan
K Burley Stephen
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/292,345 external-priority patent/US6001968A/en
Priority claimed from US08/438,431 external-priority patent/US6429290B1/en
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of HK1001495B publication Critical patent/HK1001495B/xx
Publication of HK1001495A1 publication Critical patent/HK1001495A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
HK98100386A 1994-08-17 1998-01-16 Obesity (ob) peptides capable of modulating body weight of animals, allelic variants, analogs and fragments thereof, derivatives, nucleic acid sequences, vectors, hosts and the like related thereto, and pharmaceutical compositions and related uses HK1001495A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US08/292,345 US6001968A (en) 1994-08-17 1994-08-17 OB polypeptides, modified forms and compositions
US08292345 1994-08-17
US08347563 1994-11-30
US08/347,563 US5935810A (en) 1994-08-17 1994-11-30 Mammalian ob polypeptides capable of modulating body weight, corresponding nucleic acids, and diagnostic and therapeutic uses thereof
US08438431 1995-05-10
US08/438,431 US6429290B1 (en) 1994-08-17 1995-05-10 OB polypeptides, modified forms and derivatives
US08483211 1995-06-07
US08/483,211 US6309853B1 (en) 1994-08-17 1995-06-07 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
HK1001495B HK1001495B (en) 1998-06-19
HK1001495A1 true HK1001495A1 (en) 1998-06-19

Family

ID=27501568

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98100386A HK1001495A1 (en) 1994-08-17 1998-01-16 Obesity (ob) peptides capable of modulating body weight of animals, allelic variants, analogs and fragments thereof, derivatives, nucleic acid sequences, vectors, hosts and the like related thereto, and pharmaceutical compositions and related uses

Country Status (32)

Country Link
US (1) US6309853B1 (fr)
EP (1) EP0777732B1 (fr)
JP (1) JP3479080B2 (fr)
CN (1) CN1162978B (fr)
AP (1) AP815A (fr)
BG (1) BG64710B1 (fr)
BR (1) BR9508596A (fr)
CA (1) CA2195955C (fr)
CZ (1) CZ295018B6 (fr)
DE (2) DE19531931A1 (fr)
EE (1) EE04377B1 (fr)
ES (1) ES2108663T3 (fr)
FI (1) FI121709B (fr)
GB (1) GB2292382B (fr)
GE (1) GEP20022701B (fr)
GR (1) GR970300021T1 (fr)
HK (1) HK1001495A1 (fr)
HU (1) HU223563B1 (fr)
IL (2) IL114987A (fr)
IS (1) IS4416A (fr)
LV (1) LV11868B (fr)
MD (1) MD2311G2 (fr)
MX (1) MX9701200A (fr)
NO (2) NO323847B1 (fr)
NZ (1) NZ291689A (fr)
OA (1) OA10596A (fr)
PL (1) PL183352B1 (fr)
RO (1) RO121036B1 (fr)
SI (1) SI9520090A (fr)
SK (1) SK287191B6 (fr)
TR (1) TR199501021A2 (fr)
WO (1) WO1996005309A2 (fr)

Families Citing this family (346)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310034B1 (en) 1993-05-21 2001-10-30 Ut-Battelle, Llc Agouti polypeptide compositions
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US5858967A (en) * 1995-01-20 1999-01-12 University Of Washington Appetite supression factor and related methods
US5827734A (en) * 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552523A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) * 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5567803A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) * 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) * 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) * 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) * 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) * 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
EP0725079A1 (fr) * 1995-01-31 1996-08-07 Eli Lilly And Company Protéine contre obesité
US5563245A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5594101A (en) * 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5719266A (en) * 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
EP0736599A3 (fr) * 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd Le gène d'obésité de rat, son produit génique et sa production
AU5098396A (en) * 1995-04-07 1996-10-23 Kuyus-Stiftung Cosmetic composition for treating cellulite
US5614379A (en) * 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
US5840517A (en) * 1995-04-26 1998-11-24 Eli Lilly And Company Process for preparing obesity protein analogs
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
ZA963530B (en) * 1995-05-05 1996-11-05 Hoffmann La Roche Recombinant obese (ob) proteins
DE741187T1 (de) * 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
EP0826045A1 (fr) * 1995-05-08 1998-03-04 Chiron Corporation Acides nucleiques pour traiter l'obesite
WO1996036644A1 (fr) * 1995-05-19 1996-11-21 Eli Lilly And Company Produit du gene de l'obesite
US6395509B1 (en) 1995-05-26 2002-05-28 Eli Lilly And Company DNA encoding Rhesus ob protein
CA2221824A1 (fr) * 1995-05-26 1996-11-28 Eli Lilly And Company Proteine et adn de gene ob de rhesus
EP0832220A1 (fr) 1995-06-07 1998-04-01 Amgen Inc. Compositions renfermant la proteine ob et procedes associes
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
EP0833835A4 (fr) * 1995-06-22 1999-05-26 Lilly Co Eli Intermediaires de proteines contre l'obesite, leur preparation et leur utilisation
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
EP0759441A3 (fr) * 1995-06-30 1999-06-30 Eli Lilly And Company Procédés de traitement des pathologies associées aux peptides neuropeptide Y
KR19990028388A (ko) * 1995-06-30 1999-04-15 피터 지. 스트링거 당뇨병 치료 방법
DK0865294T3 (da) * 1995-08-17 2004-06-28 Amgen Inc Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
CA2232193A1 (fr) * 1995-09-19 1997-03-27 Brigitte Elisabeth Schoner Adn codant des proteines medicinales
WO1997016550A1 (fr) * 1995-11-02 1997-05-09 Bristol-Myers Squibb Company Fragments polypeptides derives du produit genique obese
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
DE69638119D1 (de) * 1995-11-22 2010-03-11 Amgen Inc Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
WO1997020933A2 (fr) * 1995-12-06 1997-06-12 Schering Corporation VARIANTES MUTATIONNELLES DE PROTEINES DE GENES Ob CHEZ LES MAMMIFERES
US6225446B1 (en) 1995-12-06 2001-05-01 Schering Corporation Mutational variants of mammalian proteins
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US7632922B1 (en) 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
BR9612359A (pt) * 1995-12-27 1999-07-13 Genentech Inc Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
EP0877627A1 (fr) * 1996-01-25 1998-11-18 Eli Lilly And Company Composes d'analogues de proteines de l'obesite et preparations a base de ceux-ci
EP0912739A2 (fr) * 1996-03-01 1999-05-06 Amgen Inc. Compositions de proteine ob canine et procedes
CA2250570A1 (fr) * 1996-03-26 1997-10-02 Eli Lilly And Company Formulations de proteine ob
AU2810497A (en) * 1996-04-19 1997-11-12 University Of Washington Methods for inducing bone formation
US6007998A (en) * 1996-04-22 1999-12-28 Merck & Co., Inc. Leptin assay
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
CA2257140A1 (fr) * 1996-06-04 1997-12-11 The Scripps Research Institute Procedes diagnostiques et therapeutiques lies a la regulation de mobilisation d'energie, par proteine ob et anticorps ob
AR008765A1 (es) * 1996-06-06 2000-02-23 Smithkline Beecham Plc Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del
JP2002514904A (ja) * 1996-06-20 2002-05-21 メルク エンド カンパニー インコーポレーテッド 肥満に対する遺伝子治療
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US6630346B1 (en) * 1996-06-20 2003-10-07 Merck & Co., Inc. Gene therapy for obesity
EP0921820A4 (fr) * 1996-06-20 2003-01-15 Merck & Co Inc Therapie genique de l'obesite
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
US6277592B1 (en) * 1996-07-31 2001-08-21 Purina Mills, Inc. Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
US20020110857A1 (en) * 1996-07-31 2002-08-15 Spurlock Michael E. Bovine leptin protein, antisense and antibody
WO1998008512A1 (fr) * 1996-08-30 1998-03-05 Amgen Inc. Methodes pour accroitre la sensibilite d'un individu a la proteine ob par accroissement de l'affinite du recepteur de la proteine ob
CZ90999A3 (cs) * 1996-09-20 1999-06-16 Hoechst Aktiengesellschaft Farmaceutický přípravek obsahující antagonistu leptinu vhodný pro léčení inzulínové rezistence u diabetes mellitus II. typu
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
AU4582597A (en) * 1996-10-11 1998-05-11 Eli Lilly And Company Therapeutic proteins
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
NL1004559C2 (nl) * 1996-11-18 1998-05-19 Unilife Boter.
WO1998024896A2 (fr) * 1996-12-06 1998-06-11 F. Hoffmann-La Roche Ag Muteines de la proteine de l'obesite
CA2217698A1 (fr) * 1996-12-20 1998-06-20 Eli Lilly And Company Proteines contre l'obesite
EP0954588B1 (fr) * 1996-12-20 2007-01-17 Amgen Inc. Procedes et compositions comprenant une proteine de fusion ob
CA2274799A1 (fr) * 1996-12-20 1998-07-02 Eli Lilly And Company Proteines anti-obesite
EP0973534B1 (fr) * 1997-04-15 2006-11-02 Csir Extraits de plantes dotés d'une activité coupe-faim
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
CA2293504A1 (fr) * 1997-06-06 1998-12-10 Valur Emilsson Utilisation d'antagonistes de leptine pour traiter le diabete
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US5866547A (en) * 1998-01-20 1999-02-02 Beth Israel Deaconess Medical Center Methods of neuroendocrine regulation of affective disorders
EP0950417A3 (fr) 1998-02-23 2000-02-23 Pfizer Products Inc. Traitement d' anomalies du squelette
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
AU770653B2 (en) * 1998-08-12 2004-02-26 Medical Research Council Gene
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
CA2341412A1 (fr) * 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Heparinases a conception rationnelle derivees de l'heparinase i et ii
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ATE348163T1 (de) 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
CA2360347C (fr) 1998-12-31 2013-05-07 Chiron Corporation Expression amelioree de polypeptides hiv et production de particules de type viral
CZ20012406A3 (cs) * 1999-01-07 2002-03-13 Lexigen Pharmaceuticals, Corp. Exprese a export proteinů působících proti obezitě jako Fc fúzních proteinů
ATE323766T1 (de) * 1999-02-12 2006-05-15 Amgen Inc Glykosylierte leptinzusammensetzungen und zugehörige verfahren
WO2000056903A2 (fr) * 1999-03-22 2000-09-28 Zymogenetics, Inc. Methodes ameliorees de production de proteines dans la pichia transformee
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
CA2370539C (fr) * 1999-04-23 2009-01-06 Massachusetts Institute Of Technology Systeme et procede de notation de polymeres
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7160924B2 (en) 2002-07-19 2007-01-09 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
DE60025832T2 (de) 1999-08-09 2006-08-31 Emd Lexigen Research Center Corp., Billerica Mehrere zytokin-antikörper komplexen
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
CA2391080A1 (fr) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Formes d'erythropoietine dotees de proprietes ameliorees
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
JP2003525946A (ja) * 2000-03-08 2003-09-02 マサチューセッツ インスティテュート オブ テクノロジー ヘパリナーゼｉｉｉおよびその使用
ES2260219T3 (es) 2000-04-21 2006-11-01 Amgen Inc. Derivados de peptidos apo-ai/aii.
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
PT1294401E (pt) 2000-06-29 2007-11-09 Merck Patent Gmbh Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US6443013B1 (en) * 2000-08-04 2002-09-03 Samsung Electronics Co., Ltd. Rotary test fixture
BR0107175A (pt) * 2000-09-04 2002-07-02 Hyo Joon Kim Peptìdeos miméticos para epitopo de apolipoproteìna b-100, concatemero e seus peptìdeos modificados, e composição de vacina compreendendo os mesmos
DK1319183T3 (da) 2000-09-12 2009-05-18 Massachusetts Inst Technology Fremgangsmåder og produkter relateret til heparin med lav molekylvægt
EP1328260A2 (fr) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Procedes et produits associes a l'administration pulmonaires de polysaccharides
US7054758B2 (en) 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
EP1998266A3 (fr) 2001-02-19 2009-02-11 Merck Patent GmbH Procédé d'identification d'épitopes de cellules t et utilisation pour préparer des molécules avec immunogénicité réduite
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
ATE549354T1 (de) 2001-05-11 2012-03-15 Amgen Inc Peptide und damit zusammenhängende an tall-1 bindende moleküle
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
DE10145553B4 (de) * 2001-09-16 2006-06-08 Gene Architects Ag Nukleinsäure für einen Klonierungsvektor
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
ES2350924T3 (es) 2001-10-22 2011-01-28 Amgen, Inc. Uso de leptina para el tratamiento de la lipoatrofia humana y método para determinar la predisposición a dicho tratamiento.
WO2003039454A2 (fr) 2001-10-23 2003-05-15 Oklahoma Medical Research Foundation Inhibiteurs de la beta-secretase et leurs procede d'utilisation
EP2354791A1 (fr) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines a selectivite modulee
WO2003059988A2 (fr) 2002-01-14 2003-07-24 The General Hospital Corporation Polymeres de polycetal biodegradables et procedes de preparation et d'utilisation associes
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CA2387003A1 (fr) * 2002-05-21 2003-11-21 984012 Alberta Ltd. Methode d'amelioration de la productivite de l'elevage d'animaux de boucherie
AU2003254023A1 (en) 2002-07-19 2004-02-09 The General Hospital Corporation Oxime conjugates and methods for their formation and use
JP2006508056A (ja) 2002-08-28 2006-03-09 イミュネックス・コーポレーション 心臓血管疾患を治療するための組成物および方法
PT1572748E (pt) 2002-12-17 2010-09-28 Merck Patent Gmbh Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
US8491883B2 (en) 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
AU2004252571C1 (en) 2003-06-27 2012-03-01 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
ES2383328T3 (es) 2003-07-25 2012-06-20 Amgen, Inc Métodos relacionados con LDCAM y CRTAM
JP4585186B2 (ja) * 2003-07-31 2010-11-24 杏林製薬株式会社 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤
JP5537763B2 (ja) 2003-09-05 2014-07-02 ザ ジェネラル ホスピタル コーポレイション 放出システムとしてのポリアセタール薬物抱合体
WO2005042475A2 (fr) 2003-10-21 2005-05-12 Sention, Inc. Esters de carbamoyle inhibant la cholinesterase et liberant des agents pharmacologiquement actifs
DE10352510A1 (de) * 2003-11-07 2005-06-23 Forschungsinstitut Für Die Biologie Landwirtschaftlicher Nutztiere Verfahren zur Identifizierung von Wirkstoffen zur Beeinflussung der Körpermasse und des Fettansatzes
AU2004313245B2 (en) 2003-12-30 2011-04-14 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
IN2012DN03921A (fr) 2004-02-11 2015-09-04 Amylin Pharmaceuticals Inc
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
JP2008505928A (ja) 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
US20090233986A1 (en) * 2004-07-27 2009-09-17 Mount Sinai School Of Medicine Methods and compositions for using sax2
JP2008513497A (ja) 2004-09-17 2008-05-01 コメンティス，インコーポレーテッド メマプシン２βセクレターゼ活性を阻害するアミノ含有化合物およびその使用方法
KR101441026B1 (ko) 2004-09-24 2014-10-01 메소블라스트, 아이엔씨. 증폭된 다능성 간엽 전구세포 자손 및 이의 용도
DK1797127T3 (en) 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
CA2581237C (fr) 2004-09-24 2018-11-06 Angioblast Systems, Inc. Procede d'accroissement de la proliferation et/ou de la survie de cellules precurseurs mesenchymateuses (mpc)
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CA2584806C (fr) 2004-11-01 2014-06-17 Amylin Pharmaceuticals, Inc. Methodes destinees a traiter l'obesite ainsi que les maladies et affections associees a l'obesite
EP1812038A1 (fr) 2004-11-18 2007-08-01 VIB vzw Domaine de fibronectine iii servant d'antagonistes de recepteurs de la leptine
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
WO2006071802A2 (fr) 2004-12-23 2006-07-06 Ethicon Incorporated Traitement de l'ictus cerebral et d'autres troubles neurodegeneratifs aigus a base de cellules tirees de tissus puerperaux
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2006086769A2 (fr) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Analogues de gip et polypeptides hybrides de gip aux proprietes selectionnables
CA2604291A1 (fr) 2005-04-08 2006-10-19 Comentis, Inc. Composes inhibant l'activite beta-secretase et leurs methodes d'utilisation
KR101446634B1 (ko) 2005-04-12 2014-10-16 메소블라스트, 아이엔씨. 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체세포의 분리
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP2330125A3 (fr) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Polypeptides hybrides ayant des propriétés sélectionnables
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
CA2626082C (fr) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Procedes et compositions destinees au traitement de patients atteints de maladies positives pour des auto-anticorps
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
PL1971681T3 (pl) 2005-12-16 2018-01-31 Depuy Synthes Products Inc Kompozycje oraz sposoby do hamowania niepożądanej odpowiedzi immunologicznej w przypadku transplantacji z brakiem zgodności tkankowej
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
CN103255162A (zh) 2006-05-19 2013-08-21 格利科菲公司 促红细胞生成素组合物
US20080096900A1 (en) 2006-06-26 2008-04-24 Amgen Inc. Methods for treating atherosclerosis
US8778977B2 (en) 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
TW200833840A (en) 2006-10-25 2008-08-16 Amgen Inc Toxin peptide therapeutic agents
JP2010510314A (ja) 2006-11-22 2010-04-02 シーサイド セラピューティクス，エルエルシー 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
EP2738257A1 (fr) 2007-05-22 2014-06-04 Amgen Inc. Compositions et procédés pour produire des protéines de fusion bioactives
JP5658031B2 (ja) 2007-06-22 2015-01-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 薄膜凍結による安定したサブミクロンのペプチド又はタンパク質粒子の形成
PL2489731T3 (pl) 2007-07-26 2015-01-30 Amgen Inc Zmodyfikowane enzymy acylotransferaza lecytyna-cholesterol
MX2010002938A (es) 2007-09-24 2010-04-01 Comentis Inc Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
AU2009248914A1 (en) * 2008-05-21 2009-11-26 Neurotez, Inc. Methods for Treating Neurodegenerative Disorders Related to Neurofibrillary Tangles
CN102105146A (zh) 2008-05-23 2011-06-22 国立犹太保健医院 用于治疗与暴露于烷化物质有关的损伤的方法
US8501686B2 (en) 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
EP2671891A3 (fr) 2008-06-27 2014-03-05 Amgen Inc. Inhibition d'ang-2 pour traiter la sclérose en plaques
CN104230901A (zh) 2008-09-15 2014-12-24 加利福尼亚大学董事会 用于调节ire1、src和abl活性的方法和组合物
CN102281865B (zh) 2008-10-15 2017-04-05 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
US8143347B2 (en) 2008-10-15 2012-03-27 Baxter International Inc. Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
KR20120024529A (ko) * 2008-11-04 2012-03-14 니콜라오스 테자프시디스 신경섬유 매듭 및 아밀로이드 베타의 축적으로부터 기인하는 진행성 인지 기능 장애의 치료용 렙틴 조성물 및 치료 방법
US8491880B2 (en) 2008-12-10 2013-07-23 Mersana Therapeutics, Inc. Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates
PL2379088T3 (pl) 2008-12-19 2018-07-31 DePuy Synthes Products, Inc. Leczenie płuca oraz chorób i zaburzeń płucnych
PT2379087E (pt) 2008-12-19 2014-12-02 Depuy Synthes Products Llc Células derivadas do tecido do cordão umbilical para o tratamento da dor neuropática e espasticidade
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
BRPI1013409A2 (pt) 2009-03-26 2018-01-16 Advanced Tech And Regenerative Medicine Llc células de tecido de cordão umbilical humano como terapia para doença de alzheimer
US20120071401A1 (en) 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
BRPI1014942A2 (pt) 2009-06-19 2019-09-24 Medimmune Llc "polipeptídeo, ácido nucleico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição farmacêutica, e método para tratar uma doença"
EP3205647B1 (fr) 2009-08-17 2020-05-13 Memorial Sloan-Kettering Cancer Center Dérivés 2-(pyrimidin-5-yl)-thiopyrimidine en tant que modulateurs hsp70 and hsc70 pour le traitement de maladies proliferatives
WO2011029043A1 (fr) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Inhibiteurs hétéroaryles de btk
EP3461824B1 (fr) 2009-09-04 2021-08-25 Biogen MA Inc. Inhibiteurs de tyrosine kinase de bruton
CN102665718B (zh) 2009-10-06 2016-03-09 米伦纽姆医药公司 可用作pdk1抑制剂的杂环化合物
CA2780205A1 (fr) 2009-11-05 2011-05-12 Brown University Methodes de traitement des hausses de la signalisation de mtor
US20110136728A1 (en) * 2009-12-09 2011-06-09 Patricia Grasso Methods of increasing bone formation using leptin-related peptides
MX347591B (es) 2009-12-10 2017-05-03 The Regents Of The Univ Of California * Agentes de enlace amiloides.
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
CN101812450B (zh) * 2010-04-28 2012-01-11 中国农业大学 辅助鉴定具有不同体重性状鸡的方法及其专用引物
CA2813087C (fr) 2010-09-28 2020-07-21 Amylin Pharmaceuticals, Llc Polypeptides techniques de duree d'action superieure
EP2632898A4 (fr) 2010-10-29 2014-04-02 Biogen Idec Inc Inhibiteurs de tyrosine kinase hétérocycliques
RU2599249C2 (ru) 2011-02-14 2016-10-10 Аллерган, Инк. Композиции и способы применения сложноэфирных производных биматопроста
CA2836449C (fr) 2011-05-17 2021-04-27 The Regents Of The University Of California Inhibiteurs de kinase
EP2714069A4 (fr) 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc Conjugués de deux hormones longue durée
WO2012174484A2 (fr) * 2011-06-15 2012-12-20 Nse Products, Inc. Identification de marqueurs de restriction calorique et mimétiques de restriction calorique
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
AU2011374879C1 (en) 2011-08-10 2018-06-14 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US9073851B2 (en) 2011-10-28 2015-07-07 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer
MX362198B (es) 2011-12-23 2019-01-08 Depuy Synthes Products Llc Deteccion de celulas derivadas de tejido de cordon umbilical humano.
CN104379563B (zh) 2012-04-10 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
EP2858500A4 (fr) 2012-06-08 2016-04-06 Biogen Ma Inc Inhibiteurs de la tyrosine kinase de bruton
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
WO2013188452A1 (fr) 2012-06-11 2013-12-19 The Regents Of The University Of California Composés et procédés de traitement du cancer
US9090595B2 (en) 2012-08-27 2015-07-28 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
CN104684904B (zh) 2012-08-27 2017-10-13 阿勒根公司 通过使用β‑氯环戊烷的亲水性酯前药减轻中央角膜增厚
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
AU2013323426A1 (en) 2012-09-26 2015-04-23 The Regents Of The University Of California Modulation of ire1
CN111529534A (zh) 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
US9364462B2 (en) 2012-10-30 2016-06-14 The Regents Of The University Of California Alpha-1-adrenergic receptor agonist therapy
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP2953475B1 (fr) 2013-02-06 2019-07-03 Celgene Corporation Lymphocytes t modifiés ayant une spécificité améliorée
CA2903827C (fr) 2013-03-14 2021-08-10 Stefan Oscarson Agents mucolytiques thiosaccharidiques
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
MX373964B (es) 2013-03-15 2020-07-13 Verseon Corp Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
HK1220205A1 (zh) 2013-03-15 2017-04-28 Celgene Corporation 修饰的t淋巴细胞
CA2901529A1 (fr) 2013-03-15 2014-09-18 Allergan, Inc. Bimatoprost pour l'amelioration de la production de leptine
TWI642677B (zh) 2013-03-15 2018-12-01 美國加利福尼亞大學董事會 非環狀核苷膦酸二酯
US9951025B2 (en) 2013-03-15 2018-04-24 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
CA2917527C (fr) 2013-07-15 2022-06-14 Board Of Regents, The University Of Texas System Composes et methodes pour le traitement du cancer, des troubles neurologiques, du sevrage de l'ethanol, de l'anxiete, de la depression, et de la douleur neuropathique
PT3035926T (pt) 2013-08-19 2020-09-01 Univ California Compostos e métodos para tratar um distúrbio epiléptico
WO2015031799A1 (fr) 2013-08-30 2015-03-05 The Regents Of The University Of California, A California Corporation Compositions contenant des nanocristaux scintillateurs et leurs procédés d'utilisation
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
JP6672157B2 (ja) 2013-11-26 2020-03-25 ザ チルドレンズ メディカル センター コーポレーション 肥満を処置するための化合物およびその使用方法
SI3080103T1 (sl) 2013-12-11 2018-11-30 Biogen Ma Inc. Biarilne spojine, ki so uporabne za zdravljenje človeških bolezni na področju onkologije, nevrologije in imunologije
WO2015089327A1 (fr) 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Composés biaryliques utiles pour le traitement de maladies humaines en oncologie, neurologie et immunologie
EP3086792B1 (fr) 2013-12-23 2022-10-12 Memorial Sloan-Kettering Cancer Center Procédés et réactifs de radiomarquage
MX374517B (es) 2014-01-15 2025-03-06 Medimmune Ltd Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos.
CA2939569A1 (fr) 2014-02-20 2015-11-19 Allergan, Inc. Reduction de l'epaississement corneen central par utilisation de promedicaments d'esters hydrophiles de beta-chlorocyclopentanes
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
EP3143013B1 (fr) 2014-05-13 2019-12-18 Memorial Sloan Kettering Cancer Center Modulateurs de hsp70 et leur procédés de fabrication et leur utilisation
WO2016004383A1 (fr) 2014-07-03 2016-01-07 City Of Hope Antagonistes de ctla-4 ciblant spécifiquement les tumeurs
CA2957929A1 (fr) 2014-08-12 2016-02-18 Anthrogenesis Corporation Production de lymphocytes car-t se logeant dans une zone de lymphocytes b de ganglions lymphatiques, la peau ou le tractus gastro-intestinal
EA036391B1 (ru) 2014-09-15 2020-11-05 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Нуклеотидные аналоги
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2016049568A1 (fr) 2014-09-25 2016-03-31 Araxes Pharma Llc Méthodes et compositions permettant l'inhibition de la ras
CN111978310A (zh) 2014-10-02 2020-11-24 阿勒根公司 γ-内酰胺的酯前药及其用途
WO2016115275A1 (fr) 2015-01-13 2016-07-21 City Of Hope Masques de lieur peptidique de protéines de liaison au ctla4
CA3204599A1 (fr) 2015-02-25 2016-09-01 The Regents Of The University Of California Agonistes de recepteur 5ht pour le traitement de troubles
AU2016224975B2 (en) 2015-02-27 2020-10-22 The Regents Of The University Of California Small molecules that enable cartilage rejuvanation
SI3261639T1 (sl) 2015-02-27 2023-01-31 Verseon International Corporation Substituirane pirazolne spojine kot zaviralci serinskih proteaz
EA201792214A1 (ru) 2015-04-10 2018-01-31 Араксис Фарма Ллк Соединения замещенного хиназолина
JP6789239B2 (ja) 2015-04-15 2020-11-25 アラクセス ファーマ エルエルシー Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
AU2016247858B2 (en) 2015-04-17 2020-10-15 Ludwig Institute For Cancer Research Ltd. PLK4 inhibitors
MA42510A (fr) 2015-06-10 2018-06-06 Biogen Ma Inc Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
MX2021006326A (es) 2015-09-17 2022-12-16 Inhibidores de pcna.
CN105132566A (zh) * 2015-09-21 2015-12-09 上海中优生物高科技有限责任公司 毒素堆积型肥胖基因个体化干预饮品的制备方法及其系统
WO2017058768A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
WO2017058728A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
EP3356354A1 (fr) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356347A1 (fr) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058915A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines mutantes kras g12c
EP3359647A1 (fr) 2015-10-08 2018-08-15 Neurona Therapeutics Inc. Populations de cellules précurseurs neurales et leurs utilisations
TWI752920B (zh) 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EP3364977A4 (fr) 2015-10-19 2019-09-04 Araxes Pharma LLC Méthode de criblage d'inhibiteurs de ras
JP7034078B2 (ja) 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体
CN108697699A (zh) 2015-10-23 2018-10-23 苏尼西斯制药有限公司 用于治疗癌症的杂环pdk1抑制剂
CA3005089A1 (fr) 2015-11-16 2017-05-26 Araxes Pharma Llc Composes quinazoline substitues en position 2 comprenant un groupe heterocyclique substitue et leur methode d'utilisation
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
BR112018012934B1 (pt) 2015-12-24 2023-11-07 The Regents Of The University Of California Reguladores cftr e métodos de uso dos mesmos
AU2016379444B2 (en) 2015-12-24 2021-04-29 The Regents Of The University Of California CFTR regulators and methods of use thereof
US11834675B2 (en) 2015-12-30 2023-12-05 Celgene Corporation T lymphocyte production methods and t lymphocytes produced thereby
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
PL3458448T3 (pl) 2016-04-25 2021-12-06 Forma Therapeutics, Inc. Inhibitory fasn do zastosowania w leczeniu niealkoholowego stłuszczeniowego zapalenia wątroby
US20210323913A1 (en) 2016-04-29 2021-10-21 Board Of Regents, The University Of Texas System Sigma receptor binders
EP3578562B1 (fr) 2016-05-12 2021-06-23 Anacor Pharmaceuticals, Inc Dérivés de l-valinate amide benzoxaborole pour le traitement des maladies parasitaires
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US11174243B2 (en) 2016-07-21 2021-11-16 Sunesis Pharmaceuticals, Inc. Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
MX2019000962A (es) 2016-07-26 2019-08-01 Biomarin Pharm Inc Novedosas proteinas de la capside del virus adenoasociado.
US11542261B2 (en) 2016-08-17 2023-01-03 Children's Hospital Medical Center Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
US11254667B2 (en) 2016-08-17 2022-02-22 Children's Hospital Medical Center Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
ES2959990T3 (es) 2016-09-12 2024-02-29 Amryt Pharmaceuticals Inc Métodos de detección de anticuerpos neutralizantes dirigidos contra la leptina
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
CN110312711A (zh) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
EP4092049A1 (fr) 2016-10-20 2022-11-23 Celgene Corporation Récepteurs antigéniques chimériques hétérodimérisables à base de céréblon
AU2017378487B2 (en) 2016-12-15 2022-03-31 The Regents Of The University Of California Compositions and methods for treating cancer
EP3573971A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (fr) 2017-01-26 2018-08-02 Araxes Pharma Llc Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JP2020521740A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
TW201906832A (zh) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 用於癌症治療之化合物及其使用方法
CN107385020A (zh) * 2017-06-23 2017-11-24 西安医学院 瘦素在人重组fgf21蛋白活性检测中的应用
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
BR112020007204A2 (pt) 2017-10-10 2021-02-02 Syros Pharmaceuticals, Inc. compostos de pirrolotriazina e métodos de inibir tam quinases
CA3088526A1 (fr) 2018-01-16 2019-07-25 Syros Pharmaceuticals, Inc. Inhibiteurs de la kinase cycline-dependante 7 (cdk7)
CN112135825A (zh) 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
SI3773713T1 (sl) 2018-04-06 2025-08-29 Regeneron Pharmaceuticals, Inc. Protitelo, agonist leptinskega receptorja, za uporabo pri povečanju kostne mase pri osebi, ki trpi zaradi presnovne disfunkcije ali hipoleptinemije
WO2019217513A2 (fr) 2018-05-09 2019-11-14 Biomarin Pharmaceutical Inc. Méthodes de traitement de la grippe
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
WO2020055916A1 (fr) 2018-09-10 2020-03-19 The Regents Of The University Of California Agents mucolytiques de dithiolsaccharide et leurs utilisations
WO2020252487A1 (fr) 2019-06-14 2020-12-17 Children's Hospital Medical Center Ciblage thérapeutique rationnel d'états de signalisation immunitaire oncogènes dans des malignités myéloïdes par l'intermédiaire de l'enzyme de conjugaison d'ubiquitine ube2n
JP7695232B2 (ja) 2019-09-18 2025-06-18 武田薬品工業株式会社 ヘテロアリール血漿カリクレインインヒビター
ES2987744T3 (es) 2019-09-18 2024-11-18 Takeda Pharmaceuticals Co Inhibidores de calicreína plasmática y usos de los mismos
WO2021211938A1 (fr) 2020-04-17 2021-10-21 Shire Human Genetic Therapies, Inc. Formes solides d'inhibiteurs de la kallicréine plasmatique
ES3035604T3 (en) 2020-04-17 2025-09-05 Takeda Pharmaceuticals Co Forms and compositions of inhibitors of plasma kallikrein
BR112023018619A2 (pt) 2021-03-17 2023-11-28 Takeda Pharmaceuticals Co Inibidores de heteroaril de calicreína plasmática
JP2024512497A (ja) 2021-03-17 2024-03-19 武田薬品工業株式会社 血漿カリクレインの阻害剤
WO2022197789A1 (fr) 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Inhibiteurs polycycliques de kallicréine plasmatique
JP2024510503A (ja) 2021-03-17 2024-03-07 武田薬品工業株式会社 血漿カリクレイン阻害剤
CN117396473A (zh) 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶的咪唑并吡啶基抑制剂
IL309653A (en) 2021-08-06 2024-02-01 Celgene Corp Composition and methods for selective degradation of transgenic proteins
JP2025526212A (ja) 2022-07-21 2025-08-13 アンティバ バイオサイエンシズ インコーポレイテッド Ｈｐｖ感染症及びｈｐｖ誘発性新生物の治療用の組成物及び剤形
WO2024040241A1 (fr) 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Formulations pharmaceutiques, processus de préparation et méthodes d'utilisation
JP2025531207A (ja) 2022-09-15 2025-09-19 武田薬品工業株式会社 遺伝性血管性浮腫の処置のための血漿カリクレイン阻害剤としてのｎ－（（イソキノリン－６イル）メチル）－１ｈ－ピラゾール－４－カルボキサミド誘導体

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE31006E (en) 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3650090A (en) 1970-06-19 1972-03-21 Phillips Petroleum Co Analysis of gaseous mixtures
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
EP0043718B1 (fr) 1980-07-07 1984-11-28 National Research Development Corporation Lignées de cellules
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4451570A (en) 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
WO1988001213A1 (fr) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Systemes de distribution pour agents pharmacologiques
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
ATE452190T1 (de) 1988-05-13 2010-01-15 Amgen Inc Verfahren zur isolierung und reinigung von g-csf
AU4332589A (en) 1988-09-26 1990-04-18 Salk Institute Biotechnology/Industrial Associates, Inc., The Mixed feed recombinant yeast fermentation
US5102789A (en) 1989-03-15 1992-04-07 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of epideramal growth factor in pichia pastoris yeast cells
CA2006596C (fr) 1988-12-22 2000-09-05 Rika Ishikawa G-csf modifie chimiquement
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
WO1990014092A1 (fr) 1989-05-18 1990-11-29 Cell Genesys, Inc. Utilisation d'oligonucleotides mono-brins pour la modification axee sur le site de genes mammiferes in vivo
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2127458T3 (es) 1989-11-06 1999-04-16 Cell Genesys Inc Produccion de proteinas utilizando recombinacion homologa.
RU2128227C1 (ru) 1989-12-22 1999-03-27 Апплайд Резеч Системз АРС Холдинг Н.В. (NL) (Антильские острова) Способ активации транскрипционно-молчащего гена
US5139749A (en) 1990-06-22 1992-08-18 Tas, Inc. Fluidized calcining process
WO1992016192A1 (fr) 1991-03-15 1992-10-01 Amgen Inc. Administration pulmonaire d'un facteur de stimulation des populations de granulocytes
ZA924674B (en) 1991-07-02 1993-04-28 Imclone Systems Inc Cysteine depleted il-6 mutein
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
IL105406A (en) 1992-04-17 2000-01-31 Sankyo Co Derivatives of adipogenesis inhibitory factor processes for the preparation thereof and pharmaceutical compositions containing the same
ES2252732T3 (es) 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
JPH08500483A (ja) * 1992-06-19 1996-01-23 ジョスリン ダイアビーティーズ センター インコーポレイテッド 糖尿遺伝子ｒａｄ：２型糖尿病特異性遺伝子
PT669929E (pt) 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
US5574018A (en) 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5569744A (en) 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5567803A (en) 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5563245A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5525705A (en) 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
EP0725079A1 (fr) 1995-01-31 1996-08-07 Eli Lilly And Company Protéine contre obesité
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5594101A (en) 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
EP0736599A3 (fr) 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd Le gène d'obésité de rat, son produit génique et sa production
JPH08333394A (ja) 1995-04-03 1996-12-17 Takeda Chem Ind Ltd ラット肥満遺伝子、その遺伝子産物およびその製造法
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5614379A (en) 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
DE741187T1 (de) 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
WO1996036644A1 (fr) 1995-05-19 1996-11-21 Eli Lilly And Company Produit du gene de l'obesite
CA2221824A1 (fr) 1995-05-26 1996-11-28 Eli Lilly And Company Proteine et adn de gene ob de rhesus
EP0759441A3 (fr) 1995-06-30 1999-06-30 Eli Lilly And Company Procédés de traitement des pathologies associées aux peptides neuropeptide Y
KR19990028388A (ko) 1995-06-30 1999-04-15 피터 지. 스트링거 당뇨병 치료 방법
CA2232193A1 (fr) 1995-09-19 1997-03-27 Brigitte Elisabeth Schoner Adn codant des proteines medicinales
US5698389A (en) 1995-11-16 1997-12-16 Tularik, Inc. Transcriptional promoter of the murine obesity gene
JP2000505078A (ja) 1996-01-19 2000-04-25 イーライ・リリー・アンド・カンパニー 肥満症タンパク質製剤
AU1705197A (en) 1996-01-19 1997-08-11 Eli Lilly And Company Obesity protein formulations
EP0784982A3 (fr) 1996-01-19 1999-08-18 Eli Lilly And Company Préparation des protéines contre l'obésité
EP0784979A3 (fr) 1996-01-19 1999-03-03 Eli Lilly And Company Formulations contenant une protéine de l'obésité
CA2250570A1 (fr) 1996-03-26 1997-10-02 Eli Lilly And Company Formulations de proteine ob

Also Published As

Publication number Publication date
EE04377B1 (et) 2004-10-15
CN1162978A (zh) 1997-10-22
BR9508596A (pt) 1997-10-21
FI121709B (fi) 2011-03-15
CA2195955C (fr) 2012-03-13
HUT78052A (hu) 1999-07-28
NO323847B1 (no) 2007-07-09
SK287191B6 (sk) 2010-02-08
JPH09506264A (ja) 1997-06-24
DE19531931A1 (de) 1996-03-07
FI970656A0 (fi) 1997-02-17
EP0777732B1 (fr) 2011-09-28
PL319021A1 (en) 1997-07-21
GB9516947D0 (en) 1995-10-18
IL162093A0 (en) 2005-11-20
WO1996005309A3 (fr) 1996-03-21
BG101228A (en) 1997-09-30
OA10596A (en) 2002-06-26
EP0777732A1 (fr) 1997-06-11
GEP20022701B (en) 2002-05-27
SK22197A3 (en) 1998-02-04
CN1162978B (zh) 2010-06-16
IL114987A0 (en) 1995-12-08
EE9700030A (et) 1997-08-15
ES2108663T1 (es) 1998-01-01
NO970683D0 (no) 1997-02-14
SI9520090A (sl) 1998-08-31
ES2108663T3 (es) 2012-02-17
US6309853B1 (en) 2001-10-30
BG64710B1 (bg) 2005-12-30
DE777732T1 (de) 1998-01-29
MD2311G2 (ro) 2004-08-31
JP3479080B2 (ja) 2003-12-15
GB2292382B (en) 1997-07-16
MX9701200A (es) 1998-05-31
IL114987A (en) 2004-07-25
TR199501021A2 (tr) 1996-06-21
GB2292382A (en) 1996-02-21
CZ46097A3 (en) 1997-11-12
FI970656A7 (fi) 1997-02-17
WO1996005309A2 (fr) 1996-02-22
LV11868B (en) 1998-01-20
MD2311F2 (en) 2003-11-30
CA2195955A1 (fr) 1996-02-22
MD970100A (en) 1998-04-30
CZ295018B6 (cs) 2005-05-18
NO20065287L (no) 1997-04-16
GR970300021T1 (en) 1997-07-30
HU223563B1 (hu) 2004-09-28
NO970683L (no) 1997-04-16
NZ291689A (en) 2000-01-28
NO326376B1 (no) 2008-11-17
RO121036B1 (ro) 2006-11-30
IS4416A (is) 1997-01-17
AP9700919A0 (en) 1997-01-31
PL183352B1 (pl) 2002-06-28
AP815A (en) 2000-03-10
LV11868A (lv) 1997-10-20

Similar Documents

Publication Publication Date Title
HK1001495A1 (en) Obesity (ob) peptides capable of modulating body weight of animals, allelic variants, analogs and fragments thereof, derivatives, nucleic acid sequences, vectors, hosts and the like related thereto, and pharmaceutical compositions and related uses
ZA956868B (en) Modulators of body weight corresponding nucleic acids and proteins and diagnostic and therapeutic uses thereof
Sumizawa et al. Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor
Erdile et al. Characterization of a cDNA encoding the 70-kDa single-stranded DNA-binding subunit of human replication protein A and the role of the protein in DNA replication
Takeshita et al. Cloning of the γ chain of the human IL-2 receptor
US6828426B1 (en) VEGF-like factor
Beer et al. Mouse fibroblast growth factor 10: cDNA cloning, protein characterization, and regulation of mRNA expression
EP0853668B2 (fr) Genes regules et leurs utilisations
Takeda et al. Structure/function studies of human beta-cell glucokinase. Enzymatic properties of a sequence polymorphism, mutations associated with diabetes, and other site-directed mutants
CA2067744A1 (fr) Recepteur (cr1) c3b/c4b humain
US6180602B1 (en) Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
KR20200110055A (ko) miR-142-3p의 표적 서열을 포함하는 재조합 벡터
EP1049487B1 (fr) Traitement de la porphyrie intermittente aigue (aip) et d'autres maladies porphyriques
Xie et al. Isolation and expression of a full-length cDNA encoding the human GM2 activator protein
WO2000005373A3 (fr) Methodes et compositions pour le diagnostic et le traitement de troubles du poids corporel, dont l'obesite
KR101756131B1 (ko) 간세포 성장인자 및 기질세포 유발인자1알파를 이용한 말초동맥질환의 예방 또는 치료용 조성물
Manzanera et al. Mutational analysis of the highly conserved C-terminal residues of the XylS protein, a member of the AraC family of transcriptional regulators
Nittoh et al. Identification of cDNA encoding rat eosinophil cationic protein/eosinophil-associated ribonuclease
JPH10502809A (ja) 組換えｋａｔ酵素およびその調製方法
Mosca et al. Tissue expression and translational control of rat kynurenine aminotransferase/glutamine transaminase K mRNAs
UA70911C2 (uk) Поліпептид ожиріння (варіанти), відповідні нуклеїнові кислоти (варіанти) та фармацевтична композиція
CN100390286C (zh) 新酶基因及其表达产物
Elder et al. Targeting of Sp1 to a non-Sp1 site in the human neurofilament (H) promoter via an intermediary DNA-binding protein
US20040171122A1 (en) Gm-csf and/or defensin protein expression regulators in epithelial cells comprising ets transcription factor or gene encoding the same
WO2007108643A1 (fr) Nouveau gène et polypeptides du facteur de croissance dérivé des plaquettes de type b

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090817